A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update

Lee, 1997, Hepatitis B virus infection, N Engl J Med, 337, 1733, 10.1056/NEJM199712113372406 McQuillan, 1999, Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994, Am J Public Health, 89, 14, 10.2105/AJPH.89.1.14 Guane, 2004, Prevalence of HBV and risk of HBV acquisition in hepatitis B screening programs in large metropolitan cities in the United States (abstract), Hepatology, 40, 716A 2006, Screening for chronic hepatitis B among Asian/Pacific islander populations: New York City, 2005, MMWR Morb Mortal Wkly Rep, 55, 1 Keeffe, 2004, A treatment algorithm for the management of chronic hepatitis B virus infection in the United States, Clin Gastroenterol Hepatol, 2, 87, 10.1016/S1542-3565(03)00312-4 Keeffe, 2006, A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update, Clin Gastroenterol Hepatol, 4, 936, 10.1016/j.cgh.2006.05.016 Keeffe, 2007, Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B, Clin Gastroenterol Hepatol, 5, 890, 10.1016/j.cgh.2007.05.004 Lok, 2007, Chronic hepatitis B, Hepatology, 45, 507, 10.1002/hep.21513 de Franchis, 2003, EASL International Consensus Conference on Hepatitis B, 13-14 September, 2002 Geneva, Switzerland: consensus statement (long version), J Hepatol, 39, S3, 10.1016/S0168-8278(03)00378-7 Liaw, 2006, Chronic hepatitis B: treatment alert, Liver Int, 26, 47, 10.1111/j.1478-3231.2006.01374.x Fattovich, 1991, Natural history and prognostic factors for chronic hepatitis type B, Gut, 32, 294, 10.1136/gut.32.3.294 Chen, 2006, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA, 295, 65, 10.1001/jama.295.1.65 Kao, 2000, Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B, Gastroenterology, 118, 554, 10.1016/S0016-5085(00)70261-7 Frodsham, 2005, Host genetics and the outcome of hepatitis B viral infection, Transpl Immunol, 14, 183, 10.1016/j.trim.2005.03.006 Liaw, 2006, Factors influencing liver disease progression in chronic hepatitis B, Liver Int, 26, 23, 10.1111/j.1478-3231.2006.01372.x Chu, 2004, Natural history differences in perinatally versus adult acquired disease, Current Hepatitis Reports, 3, 123 Yim, 2006, Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005, Hepatology, 43, S173, 10.1002/hep.20956 Hoofnagle, 2007, Management of hepatitis B: summary of a clinical research workshop, Hepatology, 45, 1056, 10.1002/hep.21627 Lai, 2007, The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points, Ann Intern Med, 147, 58, 10.7326/0003-4819-147-1-200707030-00010 Hui, 2007, Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase, Hepatology, 46, 395, 10.1002/hep.21724 Di Bisceglie, 1987, Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers: correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy, Gastroenterology, 93, 1236, 10.1016/0016-5085(87)90250-2 Hsu, 2002, Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B, Hepatology, 35, 1522, 10.1053/jhep.2002.33638 McMahon, 2001, Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus, Ann Intern Med, 135, 759, 10.7326/0003-4819-135-9-200111060-00006 Hoofnagle, 1981, Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis, Ann Intern Med, 94, 744, 10.7326/0003-4819-94-6-744 Liaw, 1988, The development of cirrhosis in patients with chronic type B hepatitis: a prospective study, Hepatology, 8, 493, 10.1002/hep.1840080310 Yuen, 2004, HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects, Hepatology, 39, 1694, 10.1002/hep.20240 Wong, 2004, Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients, Hepatology, 40, 727, 10.1002/hep.20353 de Franchis, 1993, The natural history of asymptomatic hepatitis B surface antigen carriers, Ann Intern Med, 118, 191, 10.7326/0003-4819-118-3-199302010-00006 Hadziyannis, 2006, Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment, Semin Liver Dis, 26, 130, 10.1055/s-2006-939751 Carman, 1997, The clinical significance of surface antigen variants of hepatitis B virus, J Viral Hepat, 4, 11, 10.1111/j.1365-2893.1997.tb00155.x Okamoto, 1994, Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen, J Virol, 68, 8102, 10.1128/JVI.68.12.8102-8110.1994 Chan, 1999, Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion, Hepatology, 29, 976, 10.1002/hep.510290352 Chu, 2007, HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up, Hepatology, 45, 1187, 10.1002/hep.21612 Chen, 2002, Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection, Gastroenterology, 123, 1084, 10.1053/gast.2002.36026 Iloeje, 2007, HBV viral load less than 104 copies/mL is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B patients: an update from the R.E.V.E.A.L.-HBV study (abstract), Hepatology, 46, 640A Iloeje, 2006, Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130, 678, 10.1053/j.gastro.2005.11.016 Yuan, 2005, The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B, J Viral Hepat, 12, 373, 10.1111/j.1365-2893.2005.00603.x de Jongh, 1992, Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver, Gastroenterology, 103, 1630, 10.1016/0016-5085(92)91188-A Liaw, 2004, Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, 351, 1521, 10.1056/NEJMoa033364 Fattovich, 2002, Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients, Am J Gastroenterol, 97, 2886, 10.1111/j.1572-0241.2002.07057.x Chen, 2007, Long-term outcomes in hepatitis B: the REVEAL-HBV study, Clin Liver Dis, 11, 797, 10.1016/j.cld.2007.08.005 Mast, 2005, A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1—immunization of infants, children, and adolescents, MMWR Recomm Rep, 54, 1 Mast, 2006, A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II—immunization of adults, MMWR Recomm Rep, 55, 1 2006, Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep, 55, 1 Dentinger, 2005, Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth, Pediatr Infect Dis J, 24, 786, 10.1097/01.inf.0000176617.63457.9f Zanetti, 2005, Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study, Lancet, 366, 1379, 10.1016/S0140-6736(05)67568-X Saldanha, 2001, An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques, Vox Sang, 80, 63, 10.1046/j.1423-0410.2001.00003.x Pawlotsky, 2003, Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics, J Hepatol, 39, S31, 10.1016/S0168-8278(03)00136-3 Lindh, 2005, Dynamic range and reproducibility of hepatitis B virus (HBV) DNA detection and quantification by Cobas Taqman HBV, a real-time semiautomated assay, J Clin Microbiol, 43, 4251, 10.1128/JCM.43.8.4251-4254.2005 Janssen, 2005, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, Lancet, 365, 123, 10.1016/S0140-6736(05)17701-0 Yu, 2005, Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men, J Natl Cancer Inst, 97, 265, 10.1093/jnci/dji043 Sumi, 2003, Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease, Hepatology, 37, 19, 10.1053/jhep.2003.50036 Chu, 2007, Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B, Gastroenterology, 133, 1458, 10.1053/j.gastro.2007.08.039 Chan, 2008, High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma, J Clin Oncol, 26, 177, 10.1200/JCO.2007.13.2043 Pan, 2007, Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C, J Viral Hepat, 14, 767, 10.1111/j.1365-2893.2007.00869.x Chu, 2005, J Hepatol, 43, 411, 10.1016/j.jhep.2005.03.018 Chan, 2004, Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma, Gut, 53, 1494, 10.1136/gut.2003.033324 Kao, 2003, Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan, Gastroenterology, 125, 1916, 10.1053/j.gastro.2003.05.014 Wai, 2002, HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C, Hepatology, 36, 1425 Livingston, 2007, Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F, Gastroenterology, 133, 1452, 10.1053/j.gastro.2007.08.010 Kao, 2000, Hepatitis B genotypes and the response to interferon therapy, J Hepatol, 33, 998, 10.1016/S0168-8278(00)80135-X Bonino, 2007, Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B, Gut, 56, 699, 10.1136/gut.2005.089722 Lau, 2005, Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B, N Engl J Med, 352, 2682, 10.1056/NEJMoa043470 Hussain, 2003, Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants, J Clin Microbiol, 41, 3699, 10.1128/JCM.41.8.3699-3705.2003 Foucher, 2006, Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations, Eur J Gastroenterol Hepatol, 18, 411, 10.1097/00042737-200604000-00015 Montazeri, 2005, Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B, BMC Gastroenterol, 5, 32, 10.1186/1471-230X-5-32 Myers, 2003, Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B, J Hepatol, 39, 222, 10.1016/S0168-8278(03)00171-5 Wai, 2006, Non-invasive models for predicting histology in patients with chronic hepatitis B, Liver Int, 26, 666, 10.1111/j.1478-3231.2006.01287.x Lebensztejn, 2005, A simple noninvasive index (APRI) predicts advanced liver fibrosis in children with chronic hepatitis B, Hepatology, 41, 1434, 10.1002/hep.20736 Bruix, 2005, Management of hepatocellular carcinoma, Hepatology, 42, 1208, 10.1002/hep.20933 Perrillo, 2002, Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B, Hepatology, 36, 186, 10.1053/jhep.2002.34294 Lok, 1992, A controlled trial of interferon with or without prednisone priming for chronic hepatitis B, Gastroenterology, 102, 2091, 10.1016/0016-5085(92)90337-X Marcellin, 2007, Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (40 kD) ± lamivudine: 3-year follow-up results (abstract), J Viral Hepat, 46, S25, 10.1016/S0168-8278(07)61651-1 Prati, 2002, Updated definitions of healthy ranges for serum alanine aminotransferase levels, Ann Intern Med, 137, 1, 10.7326/0003-4819-137-1-200207020-00006 Kariv, 2006, Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study, Liver Int, 26, 445, 10.1111/j.1478-3231.2006.01197.x Nair, 2001, Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?, Hepatology, 34, 1021, 10.1053/jhep.2001.28459 Kim, 2004, Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study, BMJ, 328, 983, 10.1136/bmj.38050.593634.63 Yuen, 2005, Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications, Gut, 54, 1610, 10.1136/gut.2005.065136 Lai, 2007, The clinical significance of persistently normal ALT in chronic hepatitis B infection, J Hepatol, 47, 760, 10.1016/j.jhep.2007.07.022 Fung, 2007, Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management (abstract), Hepatology, 46, 647A Nguyen, 2007, High Prevalence of significant histologic disease in patients with chronic hepatitis B (CHB) and normal ALT (abstract), Hepatology, 46, 680A Gui, 2007, Predictors of significant histological findings in chronic hepatitis B patients with persistently normal ALT levels (abstract), Hepatology, 46, 653A Lok, 2001, Management of hepatitis B: 2000—summary of a workshop, Gastroenterology, 120, 1828, 10.1053/gast.2001.24839 Fung, 2007, Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study, Aliment Pharmacol Ther, 26, 377, 10.1111/j.1365-2036.2007.03390.x Chu, 2002, Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection, Hepatology, 36, 1408, 10.1053/jhep.2002.36949 Hadziyannis, 2007, Unrevealing the natural course of the so-called “inactive HBsAg or HBV carrier state.”, Hepatology Int, 2007, 281, 10.1007/s12072-007-9004-7 Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Hepatol Int. Open Access. DOI 10.1007/s12072-008-9080-3. Cooksley, 2004, Treatment with interferons (including pegylated interferons) in patients with hepatitis B, Semin Liver Dis, 24, 45, 10.1055/s-2004-828678 Lai, 2007, Telbivudine versus lamivudine in patients with chronic hepatitis B, N Engl J Med, 357, 2576, 10.1056/NEJMoa066422 Chang, 2006, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B, N Engl J Med, 354, 1001, 10.1056/NEJMoa051285 Sherman, 2006, Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B, Gastroenterology, 130, 2039, 10.1053/j.gastro.2006.04.007 Lai, 2006, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 354, 1011, 10.1056/NEJMoa051287 Benhamou, 2003, Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus, N Engl J Med, 348, 177, 10.1056/NEJM200301093480218 Benhamou, 2006, Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients, Hepatology, 43, 548, 10.1002/hep.21055 Dore, 2004, Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus, J Infect Dis, 189, 1185, 10.1086/380398 van Bommel, 2006, Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy, Hepatology, 44, 318, 10.1002/hep.21253 van Bommel, 2004, Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection, Hepatology, 40, 1421, 10.1002/hep.20464 Heathcote, 2007, A randomized, double-blind, comparison of tenofovir (TDF) versus adefovir dipovoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103 (abstract), Hepatology, 46, 861A Marcellin, 2007, A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102 (abstract), Hepatology, 46, 290A Chan, 2007, Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: a randomized trial, Ann Intern Med, 147, 745, 10.7326/0003-4819-147-11-200712040-00183 Perrillo, 2006, Therapy of hepatitis B: viral suppression or eradication?, Hepatology, 43, S182, 10.1002/hep.20970 Lampertico, 1997, A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum, Hepatology, 26, 1621, 10.1002/hep.510260634 Chan, 2005, A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone, Ann Intern Med, 142, 240, 10.7326/0003-4819-142-4-200502150-00006 Hui, 2006, 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection, Aliment Pharmacol Ther, 23, 1171, 10.1111/j.1365-2036.2006.02887.x Gish, 2007, Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B, Gastroenterology, 133, 1437, 10.1053/j.gastro.2007.08.025 Colonno, 2006, Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients (abstract), Hepatology, 44, 229A Colonno, 2007, Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients (abstract), J Hepatol, 46, S294, 10.1016/S0168-8278(07)62379-4 Leung, 2007, Entecavir (ETV) results in higher HBV-DNA reduction vs adefovir (ADV) in chronically infected HBeAg+ antiviral-naive adults: 48 wk results (E.A.R.L.Y Study) (abstract), J Hepatol, 46, S24, 10.1016/S0168-8278(07)61647-X Leung, 2008, Entecavir (ETV) results in higher HBV DNA reduction versus adefovir (ADV) in antiviral-naive HBeAg(+) adults with high HBV DNA: week 96 results (E.A.R.L.Y. Study) (abstract), J Hepatol, 48, S373, 10.1016/S0168-8278(08)61000-4 Bryant, 2001, Antiviral L-nucleosides specific for hepatitis B virus infection, Antimicrob Agents Chemother, 45, 229, 10.1128/AAC.45.1.229-235.2001 Lai, 2005, A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B, Gastroenterology, 129, 528, 10.1016/j.gastro.2005.05.053 Han, 2007, Telbivudine globe trial at year two: efficacy, safety, and predictors of outcome in patients with chronic hepatitis B (abstract), Gastroenterology, 132, A765 Lai, 2006, Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs lamivudine (abstract), Hepatology, 44, 22A Zeuzem, 2007, Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (the GLOBE study) (abstract), Hepatology, 46, 681A van Bommel, 2003, Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation, Gastroenterology, 124, 586, 10.1053/gast.2003.1240586b Heathcote, 2008, Tenofovir disopoxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 2 adefovir dipivoxil switch data (study 103) (abstract), J Hepatol, 48, S32, 10.1016/S0168-8278(08)60074-4 Marcellin, 2004, Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 351, 1206, 10.1056/NEJMoa040431 Marcellin, 2008, Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) with or without lamivudine: results of 4-year follow-up (abstract), J Hepatol, 48, S46, 10.1016/S0168-8278(08)60105-1 Marcellin, 2008, Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102) (abstract), J Hepatol, 48, S26, 10.1016/S0168-8278(08)60059-8 Zhu, 2006, Anti-HBV activity of in vitro combinations of tenofovir with nucleoside analogs (abstract), Hepatology, 44, 253A Peters, 2004, Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B, Gastroenterology, 126, 91, 10.1053/j.gastro.2003.10.051 Piccolo, 2007, Peginterferon-alpha-2a plus adefovir vs. peginterferon alpha-2a for 48 weeks in HBeAg-negative chronic hepatitis B: preliminary 24 week results of the Peg for B randomized multicenter trial (abstract), J Hepatol, 46, S26, 10.1016/S0168-8278(07)61652-3 Wursthorn, 2006, Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B, Hepatology, 44, 675, 10.1002/hep.21282 Sung, 2008, Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B, J Hepatol, 48, 728, 10.1016/j.jhep.2007.12.026 Hui, 2008, 96 weeks combination of adefovir dipivoxil plus emtricitabine vs adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B, J Hepatol, 48, 714, 10.1016/j.jhep.2007.10.013 Lee, 2006, Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy, Hepatology, 43, 1385, 10.1002/hep.21189 Rapti, 2007, Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B, Hepatology, 45, 307, 10.1002/hep.21534 Lampertico, 2006, Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B (abstract), Hepatology, 44, 693A Fung, 2006, Virologic response and resistance to adefovir in patients with chronic hepatitis B, J Hepatol, 44, 283, 10.1016/j.jhep.2005.10.018 Lampertico, 2007, Adefovir and lamviudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant pateints with HBeAg-negative chronic hepatitis B, J Hepatol, 46, S191, 10.1016/S0168-8278(07)62100-X Manolakopoulos, 2008, Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine, Aliment Pharmacol Ther, 27, 266, 10.1111/j.1365-2036.2007.03567.x Lampertico, 2007, Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients, Gastroenterology, 133, 1445, 10.1053/j.gastro.2007.08.079 Lampertico, 2005, Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine, Hepatology, 42, 1414, 10.1002/hep.20939 Reijnders, 2007, Entecavir: A rescue therapy for chronic hepatitis B patients with a limited virological response to adefovir (abstract), Hepatology, 46, 660A van Boemmel, 2007, First multicenter evaluation of the efficacy of tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfection (abstract), Hepatology, 46, 270A van Boemmel, 2007, Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir (abstract), Hepatology, 46, 664A van Bommel, 2008, A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfected patients with prior nucleo(t)ide analog experience (abstract), J Hepatol, 48, S32, 10.1016/S0168-8278(08)60075-6 Tan, 2008, Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations, J Hepatol, 48, 391, 10.1016/j.jhep.2007.09.020 Locarnini, 2007, Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV, Antivir Ther, 12, H15, 10.1177/135965350701203S03 Lok, 2003, Long-term safety of lamivudine treatment in patients with chronic hepatitis B, Gastroenterology, 125, 1714, 10.1053/j.gastro.2003.09.033 Fung, 2004, Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B, J Viral Hepat, 11, 432, 10.1111/j.1365-2893.2004.00556.x Manesis, 2007, Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels, Antivir Ther, 12, 73, 10.1177/135965350701200107 Gish, 2007, A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B, Am J Gastroenterol, 102, 2718, 10.1111/j.1572-0241.2007.01449.x Hadziyannis, 2006, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years, Gastroenterology, 131, 1743, 10.1053/j.gastro.2006.09.020 Keeffe, 2008, Chronic hepatitis B: preventing, detecting, and managing viral resistance, Clin Gastroenterol Hepatol, 6, 268, 10.1016/j.cgh.2007.12.043 Liaw, 2001, Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B, Antivir Chem Chemother, 12, 67 Lok, 2007, Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management, Hepatology, 46, 254, 10.1002/hep.21698 Colonno, 2006, Entecavir resistance is rare in nucleoside naive patients with hepatitis B, Hepatology, 44, 1656, 10.1002/hep.21422 Colonno, 2005, Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients (abstract), Hepatology, 42, 573A Shaw, 2006, HBV drug resistance: mechanisms, detection and interpretation, J Hepatol, 44, 593, 10.1016/j.jhep.2006.01.001 Stuyver, 2001, Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region, Hepatology, 33, 751, 10.1053/jhep.2001.22166 Sertoz, 2005, Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B, J Chemother, 17, 514, 10.1179/joc.2005.17.5.514 Di Bisceglie, 2006, Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleioside-treated hepatitis B patients (abstract), Hepatology, 44, 230A Realdi, 1994, Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study—the Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP), J Hepatol, 21, 656, 10.1016/S0168-8278(94)80115-0 Fattovich, 1995, Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B: the EUROHEP Study Group on Hepatitis B Virus and Cirrhosis, Hepatology, 21, 77, 10.1016/0270-9139(95)90411-5 Chu, 2006, Hepatitis B virus-related cirrhosis: natural history and treatment, Semin Liver Dis, 26, 142, 10.1055/s-2006-939752 Yuen, 2003, Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma, Hepatology, 37, 562, 10.1053/jhep.2003.50098 Homann, 1991, High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection, J Acquir Immune Defic Syndr, 4, 416 Thio, 2002, HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS), Lancet, 360, 1921, 10.1016/S0140-6736(02)11913-1 Konopnicki, 2005, Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort, AIDS, 19, 593, 10.1097/01.aids.0000163936.99401.fe Filippini, 2006, Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy, AIDS, 20, 1253, 10.1097/01.aids.0000232232.41877.2a Shire, 2007, The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients, J Acquir Immune Defic Syndr, 44, 309, 10.1097/QAI.0b013e31802e29a9 Frank, 2007, Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients, J Acquir Immune Defic Syndr, 44, 315, 10.1097/QAI.0b013e31802ea499 Colin, 1999, Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men, Hepatology, 29, 1306, 10.1002/hep.510290447 Soriano, 2006, Management of chronic hepatitis B and C in HIV-coinfected patients, J Antimicrob Chemother, 57, 815, 10.1093/jac/dkl068 Alberti, 2005, Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients, J Hepatol, 42, 615, 10.1016/j.jhep.2005.03.003 Hammer, 2006, Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel, JAMA, 296, 827, 10.1001/jama.296.7.827 McMahon, 2007, The HBV drug entecavir: effects on HIV-1 replication and resistance, N Engl J Med, 356, 2614, 10.1056/NEJMoa067710 Benhamou, 1996, Effects of lamivudine on replication of hepatitis B virus in HIV-infected men, Ann Intern Med, 125, 705, 10.7326/0003-4819-125-9-199611010-00001 Matthews, 2006, Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy, AIDS, 20, 863, 10.1097/01.aids.0000218550.85081.59 Benhamou, 1999, Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients, Hepatology, 30, 1302, 10.1002/hep.510300525 Thio, 2007, Treatment of HIV/HBV coinfection: clinical and virologic issues, AIDS Rev, 9, 40 Yeo, 2000, Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors, J Med Virol, 62, 299, 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0 Yeo, 2006, Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy, Hepatology, 43, 209, 10.1002/hep.21051 Lim, 2007, The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis, Eur J Haematol, 79, 132, 10.1111/j.1600-0609.2007.00878.x Esteve, 2004, Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis, Gut, 53, 1363, 10.1136/gut.2004.040675 Sarrecchia, 2005, HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb, J Infect Chemother, 11, 189, 10.1007/s10156-005-0385-Z Oniankitan, 2004, Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C, J Rheumatol, 31, 107 Mindikoglu, 2006, Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention, Clin Gastroenterol Hepatol, 4, 1076, 10.1016/j.cgh.2006.05.027 Li, 2006, Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma, Cancer, 106, 1320, 10.1002/cncr.21701 Kohrt, 2006, Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection, Aliment Pharmacol Ther, 24, 1003, 10.1111/j.1365-2036.2006.03081.x Lau, 2003, Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy, Gastroenterology, 125, 1742, 10.1053/j.gastro.2003.09.026 Hui, 2005, Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy, Gut, 54, 1597, 10.1136/gut.2005.070763 Chan, 2002, Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients, Hepatology, 36, 1246, 10.1053/jhep.2002.36156 Wang, 2003, Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies, J Med Virol, 71, 360, 10.1002/jmv.10493 Shiraki, 2000, Perinatal transmission of hepatitis B virus and its prevention, J Gastroenterol Hepatol, 15, E11, 10.1046/j.1440-1746.2000.02098.x Shapiro, 1992, Impact of hepatitis B virus infection on women and children, Infect Dis Clin North Am, 6, 75, 10.1016/S0891-5520(20)30426-8 Beasley, 1983, Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine, Lancet, 2, 1099, 10.1016/S0140-6736(83)90624-4 Lo, 1985, Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers, J Infect Dis, 152, 817, 10.1093/infdis/152.4.817 Wong, 1984, Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin: double-blind randomised placebo-controlled study, Lancet, 1, 921, 10.1016/S0140-6736(84)92388-2 Khuroo, 2003, Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy, J Viral Hepat, 10, 61, 10.1046/j.1365-2893.2003.00398.x van Zonneveld, 2003, Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection, J Viral Hepat, 10, 294, 10.1046/j.1365-2893.2003.00440.x van Nunen, 2000, Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients, J Hepatol, 32, 1040, 10.1016/S0168-8278(00)80112-9 Kazim, 2002, Vertical transmission of hepatitis B virus despite maternal lamivudine therapy, Lancet, 359, 1488, 10.1016/S0140-6736(02)08425-8